AHU-377 - CAS 149709-62-6
Catalog number: B0084-458470
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C24H29NO5
Molecular Weight:
411.49
COA:
Inquire
Targets:
Neprilysin
Description:
Sacubitril, also known as AHU377 or LCZ696, is angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases. LBQ657 inhibits the enzyme neprilysin, which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure lowering peptides that work mainly by reducing blood volume.
Purity:
>98%
Synonyms:
Sacubitril; AHU 377; AHU377
MSDS:
Inquire
Application:
For research used only
InChIKey:
PYNXFZCZUAOOQC-UTKZUKDTSA-N
InChI:
InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1
Canonical SMILES:
CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O
1.[Angiotensin-receptor- and neprilysin-inhibition: a new option against heart failure].
Bruhn C Med Monatsschr Pharm. 2016 Jan;39(1):4-8.
The molecular combination of sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It is usually administered in conjunction with other heart failure therapies, instead of an ACE inhibitor or an angiotensin-receptor blocker (ARB). In studies, sacubitril/ valsartan was superior to enalapril in reducing the risks of death and hospitalization for heart failure. Possible side effects of sacubitril/valsartan are hypotension, angioedema, impaired renal function and elevation in serum potassium levels. The drug should not be used in times of pregnancy and breast feeding, in patients with servere hepatic impairment (Child-Pugh C) and in combination with aliskiren in patients with diabetes.
2.Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA;Brown NJ Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622.
Heart failure affects ≈5.7 million people in the United States alone. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists have improved mortality in patients with heart failure and reduced ejection fraction, but mortality remains high. In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramolecular complex. Sacubitril is converted by esterases to LBQ657, which inhibits neprilysin, the enzyme responsible for the degradation of the natriuretic peptides and many other vasoactive peptides. Thus, this combined angiotensin receptor antagonist and neprilysin inhibitor addresses 2 of the pathophysiological mechanisms of heart failure: activation of the renin-angiotensin-aldosterone system and decreased sensitivity to natriuretic peptides. In the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, valsartan/sacubitril significantly reduced mortality and hospitalization for heart failure, as well as blood pressure, compared with enalapril in patients with heart failure, reduced ejection fraction, and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriuretic peptide.
3.Current treatment of heart failure with reduction of left ventricular ejection fraction.
Aronow WS Expert Rev Clin Pharmacol. 2016 Dec;9(12):1619-1631. Epub 2016 Oct 11.
Heart failure is the commonest cause of hospitalization and of rehospitalization This review paper is a comprehensive review of current treatment of heart failure in 2016. The target of this review is all health care professionals who treat patients with heart failure. Areas covered: This article discusses stages of heart failure, treatment of heart failure with general measures, and drug therapy with diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, aldosterone antagonists, isosorbide dinitrate plus hydralazine, digoxin, other neurohormonal antagonists, sacubitril/valsartan, calcium channel blockers, and ivabradine. This article also discusses treatment of heart failure with use of cardiac resynchronization therapy, implantable cardioverter-defibrillators, and surgical therapy, and management of end-stage heart failure. This paper was written after an extensive Medline search reviewing articles written from 1970 through May, 2016. Expert commentary: Our approach as physicians must emphasize prevention of heart failure as well as treating it. Risk factors for developing heart failure, especially hypertension, must be better controlled starting in childhood.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Neprilysin Products


CAS 162042-44-6 L-371,257

L-371,257
(CAS: 162042-44-6)

L-371,257 is a potent and high affinity human oxytocin (OT) receptor antagonist with Ki value of 4.6 nM. It displays > 800-fold selectivity over human arginine ...

CAS 112573-73-6 Ecadotril

Ecadotril
(CAS: 112573-73-6)

Ecadotril is a neutral endopeptidase(NEP) inhibitor and determined by the presence of peptidase family M13 as a neutral endopeptidase inhibited by phosphoramido...

CAS 149690-05-1 Sacubitril sodium

Sacubitril sodium
(CAS: 149690-05-1)

Sacubitril, also known as AHU377, is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor b...

CAS 149709-62-6 AHU-377

AHU-377
(CAS: 149709-62-6)

Sacubitril, also known as AHU377 or LCZ696, is angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. ...

CAS 160312-62-9 L-368,899 hydrochloride

L-368,899 hydrochloride
(CAS: 160312-62-9)

L-368,899 hydrochloride is the hydrochloride salt of L-368,899, which is a non-peptide, orally active and potent oxytocin receptor antagonist with IC50 value of...

CAS 1369773-39-6 AHU-377 hemicalcium salt

AHU-377 hemicalcium salt
(CAS: 1369773-39-6)

LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). Oral administration of LCZ696 caused ...

CAS 100845-83-8 SQ28603

SQ28603
(CAS: 100845-83-8)

SQ28603 is a selective neutral endopeptidase (NEP 3.4.24.11) inhibitor.

Chemical Structure

CAS 149709-62-6 AHU-377

Quick Inquiry

Verification code

Featured Items